Author Correction: Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells

Correction to: Scientific Reports 10.1038/s41598-022-19993-w, published online 16 September 2022

The original version of this Article contained an error, where the mention of “mRNA” was inappropriate.

As a result, in the Introduction,

“Therapeutic Ab drugs targeting SARS-CoV-2 S-protein have shown high preventive efficacy against disease development^1,2,3. In addition, current SARS-CoV-2 mRNA vaccines for humans also target the S-protein on viruses as a critical antigen⁴. These mRNA vaccines generate robust neutralizing Abs^5,6,7, but for both Ab drugs and vaccines targeting the S-protein, the possible induction of Ab-dependent enhancement (ADE) of infection is a concern^8,9,10,11.”

now reads:

“Therapeutic Ab drugs targeting SARS-CoV-2 S-protein have shown high preventive efficacy against disease development^1,2,3. In addition, current SARS-CoV-2 vaccines for humans also target the S-protein on viruses as a critical antigen⁴. These vaccines generate robust neutralizing Abs^5,6,7, but for both Ab drugs and vaccines targeting the S-protein, the possible induction of Ab-dependent enhancement (ADE) of infection is a concern^8,9,10,11.”

The original Article has been corrected.